GRCE vs HBAN · $35.0M cap vs P/E 13, rev $1.56B
Grace Therapeutics, Inc. (GRCE) versus Huntington Bancshares Incorporated (HBAN) — a side-by-side from cached financials, not a winner call.
Grace Therapeutics, Inc. (GRCE) is a biotechnology company listed on US.
Huntington Bancshares Incorporated (HBAN) is a banks - regional company listed on US.
GRCE does not have a complete income-statement cache yet.
Latest reported HBAN revenue for 2025-12-31 was $1.56B. Net income was $2.21B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
GRCE currently screens at market cap $35.0M. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
Not investment advice. Open the GRCE and HBAN stock pages for the full models.
Not investment advice.